Trastuzumab for the treatment of HER2-positive metastatic gastric cancer

TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: review decision - October 2013  information

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 106 KB)

TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: review proposal information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (PDF 105 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 366 KB)

TA208 Gastric cancer (HER2-positive metatastic) - trastuzumab: press release information

Gastric cancer (HER2-positive metastatic) - trastuzumab: equality impact assessment

Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination information

Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination

Gastric cancer (HER2-positive metastatic) - trastuzumab: final appraisal determination (PDF 301 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: response to consultee, commentator and public comments on the ACD and comments from website consultation

Gastric cancer (HER2-positive metastatic) - trastuzumab: response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 263 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: consultee and commentator comments on the ACD

Gastric cancer (HER2-positive metastatic) - trastuzumab: Cancer Research UK response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Cancer Research UK response (PDF 151 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: Centre for Reviews and Dissemination - ERG response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Centre for Reviews and Dissemination - ERG response (PDF 127 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: Roche response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Roche response (PDF 643 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Nursing response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Nursing response (PDF 59 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Physicians/NCRI/RCR/ACP/JCCO response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Royal College of Physicians/NCRI/RCR/ACP/JCCO response (PDF 76 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: Welsh Assembly Government response

Gastric cancer (HER2-positive metastatic) - trastuzumab: Welsh Assembly Government response (PDF 135 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: public comments on the ACD

Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public through the NICE website

Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public through the NICE website (PDF 90 KB)

Gastric cancer (HER2-positive metastatic) - trastuzumab: comments received from the public by letter

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): appraisal consultation document information

Evaluation report

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): pre-meeting briefing

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): pre-meeting briefing (PDF 129 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): evidence review group's report

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): evidence review group's report (PDF 625 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): addendum to the Evidence Review group report

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): addendum to the Evidence Review group report (PDF 13 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): ERG response to inaccuracies

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): ERG response to inaccuracies (PDF 25 KB)

Non-manufacturer submissions

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): non-manufacturer submissions

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): non-manufacturer submissions (PDF 53 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): RCP non-manufacturer statement

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): RCP non-manufacturer statement (PDF 31 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): Roche Pharmaceuticals

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): Roche Pharmaceuticals (PDF 1.8 MB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): NICE clarification letter

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): NICE clarification letter (PDF 38 KB)

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): manufacturer response

NICE consults on new treatment for metastatic gastric cancer information

Download PDF version

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the provisional matrix

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): response to consultee and commentator comments on the draft scope

Gastric cancer (advanced HER-2 positive) - trastuzumab (herceptin): final scope